Jeffrey S. Albert

Pharmacologic Schizophrenia

Herausgegeben von Wood, Michael W.

• Gebundenes Buch

Produktbeschreibung

Covering a wide range of receptors and molecular targets, this book provides a comprehensive resource for neuro drug discovery and molecular targets for schizophrenia. Focusing on current research and applications, the text describes novel mechanisms of action that can overcome shortcomings in existing schizophrenia drugs.

---

This book provides a comprehensive resource for neuro drug discovery and molecular targets for schizophrenia, from current therapies to evolving targets. The coverage begins with a discussion of prevalence and etiology, and an introduction to current therapies (which treat only certain, "positive" symptoms), as well as the rise of interest in addressing untreated symptoms. Subsequent sections focus on each major mechanistic hypothesis, beginning with a chapter that serves as an introduction and overview. Within these models, chapters focus on each major pharmacological target and address both the neurobiological and chemical aspects of that target.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 494
• Erscheinungstermin: 10. Juli 2012
• Englisch
• Abmessung: 240mm x 161mm x 31mm
• Gewicht: 815g
• ISBN-13: 9780470322826
• ISBN-10: 0470322829
• Artikelnr.: 34743779

Autorenporträt

JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies. MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.

Inhaltsangabe

Preface vii
Contributors xi
Introduction 1
Alan J. Cross
1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5
Aurelija Jucaite and Svante Nyberg
2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37
Philip G. Strange
3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51
Kevin N. Boyd and Richard B. Mailman
4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for
Schizophrenia 85
Judith A. Siuciak and William J. Pitts
5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115
Joseph T. Coyle, Alo Basu, and Michael Benneyworth
6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric
Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the
Treatment of Schizophrenia 143
Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz,
and James A. Monn
7 AMPA Receptor Positive Modulators 187
John A. Morrow, John K.F. Maclean, and Craig Jamieson
8 Progress in the Exploration and Development of GlyT1 Inhibitors for
Schizophrenia 233
Jeffrey S. Albert and Michael W. Wood
9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies
for the Treatment of Schizophrenia: A Pharmacological and Chemical
Perspective 255
Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones
10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia
273
Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery,
Jonathan Gross, and Karen L. Marquis
11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a
Short History 295
Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic
12 ¿7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
319
Mihály Hajós and Bruce N. Rogers
13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development
of Therapeutics for Schizophrenia 355
Christian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu
14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of
Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381
Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson
15 GABA and Schizophrenia 425
John H. Kehne and George D. Maynard
Index 469